Semaglutide does not appear to increase the risk of developing neovascular age-related macular degeneration in patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results